Pre-eclampsia and expression of heparin-binding EGF-like growth factor. 2002

Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI 48201-1415, USA.

BACKGROUND Pre-eclampsia is a disorder of pregnancy associated with poor extravillous cytotrophoblast invasion and above-normal rates of apoptosis in the trophoblast. Heparin-binding epidermal-growth-factor-like growth factor (HB-EGF) has strong cytoprotective activity and is an important signalling protein that regulates trophoblast invasion during early placentation. We aimed to establish whether HB-EGF expression is altered in placentae of pre-eclamptic women. METHODS We assessed the expression of HB-EGF mRNA and protein by in-situ hybridisation and immunohistochemical techniques, respectively, in archived placental tissues from pregnancies terminated at around 20 weeks of gestation, and from women delivering between weeks 19 and 35 of gestation with preterm labour, small for gestational age infants, or pre-eclampsia. RESULTS HB-EGF mRNA and protein were expressed in villous and extravillous cytotrophoblast cells up to week 35 of gestation in placentae from women who delivered preterm. Similar levels of HB-EGF protein were found in the placentae of women who were not in labour. HB-EGF expression was reduced about five-fold (p=0.0001) in pre-eclamptic pregnancies. Fetal growth retardation, which has been linked with shallow trophoblast invasion and moderate apoptosis, was associated with placentae expressing intermediate levels of HB-EGF. CONCLUSIONS In pre-eclampsia, deficient HB-EGF signalling during placental development could impair trophoblast survival, differentiation, and invasion, leading to poor placental perfusion and hypertension.

UI MeSH Term Description Entries
D007091 Image Processing, Computer-Assisted A technique of inputting two-dimensional or three-dimensional images into a computer and then enhancing or analyzing the imagery into a form that is more useful to the human observer. Biomedical Image Processing,Computer-Assisted Image Processing,Digital Image Processing,Image Analysis, Computer-Assisted,Image Reconstruction,Medical Image Processing,Analysis, Computer-Assisted Image,Computer-Assisted Image Analysis,Computer Assisted Image Analysis,Computer Assisted Image Processing,Computer-Assisted Image Analyses,Image Analyses, Computer-Assisted,Image Analysis, Computer Assisted,Image Processing, Biomedical,Image Processing, Computer Assisted,Image Processing, Digital,Image Processing, Medical,Image Processings, Medical,Image Reconstructions,Medical Image Processings,Processing, Biomedical Image,Processing, Digital Image,Processing, Medical Image,Processings, Digital Image,Processings, Medical Image,Reconstruction, Image,Reconstructions, Image
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D011225 Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. Toxemias, Pregnancy,EPH Complex,EPH Gestosis,EPH Toxemias,Edema-Proteinuria-Hypertension Gestosis,Gestosis, EPH,Hypertension-Edema-Proteinuria Gestosis,Preeclampsia,Preeclampsia Eclampsia 1,Pregnancy Toxemias,Proteinuria-Edema-Hypertension Gestosis,Toxemia Of Pregnancy,1, Preeclampsia Eclampsia,1s, Preeclampsia Eclampsia,EPH Toxemia,Eclampsia 1, Preeclampsia,Eclampsia 1s, Preeclampsia,Edema Proteinuria Hypertension Gestosis,Gestosis, Edema-Proteinuria-Hypertension,Gestosis, Hypertension-Edema-Proteinuria,Gestosis, Proteinuria-Edema-Hypertension,Hypertension Edema Proteinuria Gestosis,Of Pregnancies, Toxemia,Of Pregnancy, Toxemia,Pre Eclampsia,Preeclampsia Eclampsia 1s,Pregnancies, Toxemia Of,Pregnancy Toxemia,Pregnancy, Toxemia Of,Proteinuria Edema Hypertension Gestosis,Toxemia Of Pregnancies,Toxemia, EPH,Toxemia, Pregnancy,Toxemias, EPH
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011263 Pregnancy Trimester, Third The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation. Pregnancy, Third Trimester,Trimester, Third,Last Trimester,Last Trimesters,Pregnancies, Third Trimester,Pregnancy Trimesters, Third,Third Pregnancy Trimester,Third Pregnancy Trimesters,Third Trimester,Third Trimester Pregnancies,Third Trimester Pregnancy,Third Trimesters,Trimester, Last,Trimesters, Last,Trimesters, Third
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D005260 Female Females

Related Publications

Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
December 1997, Biochimica et biophysica acta,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
December 2000, Cytokine & growth factor reviews,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
August 2005, Seminars in pediatric surgery,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
December 1994, Proceedings of the National Academy of Sciences of the United States of America,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
January 2012, The journal of obstetrics and gynaecology research,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
October 1996, International journal of cancer,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
January 2001, Anticancer research,
Richard E Leach, and Roberto Romero, and Yeon Mee Kim, and Tinnakorn Chaiworapongsa, and Brian Kilburn, and Sanjoy K Das, and Sudhansu K Dey, and Anthony Johnson, and Faisal Qureshi, and Suzanne Jacques, and D Randall Armant
March 1998, Frontiers in bioscience : a journal and virtual library,
Copied contents to your clipboard!